Methodology and Baseline Data of a Comparative Exploratory Double-Blinded Randomized Study of Intravenous Iron on Fibroblast Growth Factor 23 and Phosphate in Chronic Kidney Disease
Modern intravenous iron compounds (e.g., ferric carboxymaltose [FCM] and ferric derisomaltose [FDI]) are utilized in the treatment of iron deficiency anemia in non-dialysis-dependent chronic kidney disease (ND-CKD). Product-specific alterations in the metabolism of fibroblast growth factor 23 (FGF-2...
Saved in:
Main Authors: | Xenophon Kassianides (Author), Sunil Bhandari (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2023-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
by: Xenophon Kassianides, et al.
Published: (2021) -
The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study
by: Xenophon Kassianides, et al.
Published: (2021) -
Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease
by: Faisal Nuhu, et al.
Published: (2019) -
Intravenous Irons: From Basic Science to Clinical Practice
by: Sunil Bhandari, et al.
Published: (2018) -
HIGH CIRCULATING LEVEL OF FIBROBLAST GROWHT FACTOR-23 PROMOTES RENAL EXCRETION OF PHOSPHATE IN HEMODIALYSIS PATIENTS WITH RESIDUAL RENAL FUNCTION
by: Mengjing Wang, et al.
Published: (2012)